Vitamin D deficiency is one of the most prevalent and most undertreated nutritional deficiencies in the United States - and it is hiding in plain sight in your patient population. For providers practicing in metabolic health, weight management, or hormone optimization, understanding vitamin D status is not optional. It is a foundational piece of the clinical picture that directly affects treatment outcomes.
This article covers the prevalence data, the risk factors most relevant to your patients, how to interpret lab values accurately, and why routine screening at intake is one of the highest-yield additions you can make to your clinical workflow.
HOW COMMON IS VITAMIN D DEFICIENCY?
The numbers are significant. Research published in major peer-reviewed journals consistently shows that approximately 40 to 50 percent of the general adult population in the United States has vitamin D levels below the threshold considered optimal for health. When you narrow the focus to higher-BMI patients, patients with darker skin tones, patients over 60, or patients with limited sun exposure, prevalence rates climb considerably higher.
In a typical metabolic health practice, it is reasonable to expect that the majority of new patients will present with suboptimal vitamin D levels. This is not a rare finding - it is the norm.
WHY YOUR PATIENT POPULATION IS AT HIGHER RISK
Several factors make the patients most likely to seek care in your practice disproportionately vulnerable to vitamin D deficiency.
Obesity and higher BMI. Vitamin D is a fat-soluble vitamin, meaning it is stored in adipose tissue. In patients with higher body fat percentages, vitamin D gets sequestered in fat cells and becomes less bioavailable in the bloodstream. This volumetric dilution effect means that a higher-BMI patient needs significantly more vitamin D to achieve the same serum level as a lean individual. Research suggests that obese patients may require two to three times the standard supplementation dose to reach optimal levels.
GLP-1 therapy patients. Patients initiating semaglutide or tirzepatide are often in the early stages of significant dietary restriction. If their diet was already limited in vitamin D-rich foods - fatty fish, egg yolks, fortified dairy - further restriction can worsen an already suboptimal baseline. Screening at the start of GLP-1 therapy gives you an important baseline and an opportunity to intervene early.
BHRT patients. Vitamin D plays a direct role in steroid hormone synthesis and receptor sensitivity. Patients with deficient vitamin D levels may have a blunted response to hormone therapy. Optimizing vitamin D before or alongside initiating BHRT can improve treatment outcomes and reduce the need for dose adjustments.
Geographic and lifestyle factors. Patients living in northern latitudes, those who work indoors, those who consistently use sunscreen, and those with darker skin tones that reduce UV absorption are all at elevated risk regardless of diet or supplementation habits.
WHAT LAB VALUES ACTUALLY MEAN
The standard lab reference range for vitamin D - 25-hydroxyvitamin D, or 25(OH)D - lists deficiency as below 20 ng/mL and insufficiency as 20 to 29 ng/mL. Many labs consider anything above 30 ng/mL to be within normal range.
However, the clinical and functional medicine literature consistently supports a higher optimal range for overall health. Most integrative and functional practitioners target 50 to 80 ng/mL as the optimal range for their patients, with some evidence supporting levels up to 100 ng/mL in certain populations.
The distinction between "normal" and "optimal" matters in practice. A patient with a level of 32 ng/mL will be flagged as normal on a standard lab report - but that level is unlikely to support optimal immune function, mood regulation, hormone synthesis, or metabolic health. Understanding this gap between the reference range and the functional optimum is what allows you to treat the patient in front of you rather than the lab value on a page.
THE CLINICAL CONSEQUENCES OF UNTREATED DEFICIENCY
Vitamin D deficiency affects multiple body systems simultaneously, and its consequences extend well beyond the bone health concerns most providers associate with it.
Immune function. Vitamin D receptors are present on virtually every immune cell. Deficiency is associated with increased susceptibility to infection, dysregulated immune response, and higher levels of systemic inflammation - a concern for any patient with metabolic disease.
Mood and mental health. Vitamin D deficiency is strongly associated with depression and seasonal affective disorder. For patients already dealing with the psychological burden of obesity, weight loss challenges, or hormonal dysregulation, untreated deficiency can compound mood symptoms significantly.
Insulin sensitivity and metabolic function. Research has shown an association between vitamin D deficiency and insulin resistance. In patients on GLP-1 therapy for metabolic reasons, suboptimal vitamin D may be a contributing factor to slower-than-expected treatment response.
Hormone synthesis and receptor sensitivity. Vitamin D functions as a steroid hormone precursor. It supports the synthesis of sex hormones and influences receptor sensitivity at the cellular level. BHRT patients who are deficient may not respond as robustly to hormone therapy as those with optimized vitamin D levels.
Muscle function and pain. Deficiency is associated with muscle weakness, diffuse musculoskeletal pain, and fatigue - symptoms that are often attributed to other causes and lead to unnecessary workup when vitamin D is the underlying issue.
WHY ROUTINE SCREENING MATTERS
The case for including vitamin D in your standard intake panel is straightforward. Deficiency is common, consequences are significant, testing is inexpensive, and treatment is simple. There is very little clinical downside to knowing your patient's vitamin D status at baseline.
More importantly, optimizing vitamin D at the start of treatment - whether that treatment is GLP-1 therapy, BHRT, or a comprehensive metabolic program - gives your patients the best possible foundation for success. Providers who screen routinely find that vitamin D deficiency is one of the most frequently identified and most easily corrected factors contributing to suboptimal outcomes.
Adding a 25(OH)D level to your intake lab panel takes seconds to order and can meaningfully change your clinical approach for a large proportion of your patients.
BOTTOM LINE
Vitamin D deficiency is not a niche finding. It is a widespread, clinically significant condition that disproportionately affects the patients most likely to be seeking care in your practice. Routine screening, accurate interpretation of lab values against functional rather than reference range targets, and proactive treatment are simple, high-yield interventions that improve outcomes across your entire patient population.
Responses